Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial availability of the RED ...

BOSTON--(BUSINESS WIRE)--Penumbra, Inc. (NYSE:PEN), a global interventional therapies company, today announced U.S. commercial availability of its most advanced thrombectomy device, the ACE™68 ...

The FDA says it received over 200 reports associated with Penumbra’s catheter, including ‘deaths, serious injuries, and malfunctions.’ Penumbra (PEN) shares slumped Wednesday after the medical device ...

ALAMEDA, Calif., Dec. 15, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it is voluntarily recalling all configurations of the Penumbra JET® 7 Reperfusion Catheter with Xtra Flex ...

Penumbra has issued an urgent recall of all configurations of the Penumbra JET 7 Reperfusion Catheter With Xtra Flex Technology (JET 7 Xtra Flex), owing to the risk for "unexpected death or serious ...

ALAMEDA, Calif. – Penumbra, Inc., a global healthcare company focused on innovative therapies, today announced enrollment of the first patient into the CHEETAH study, a prospective, multi-center U.S.

In more than a dozen research papers over the past decade, an academic by the name of Dr. Antik Bose appeared to tout the reliability of catheters and other medical products made by Penumbra Inc. An ...

Now available in the U.S., RED™ 62 is engineered with optimized trackability to help navigate the complex distal vessel anatomy in the brain and deliver powerful aspiration for the removal of blood ...

About the ACE68 Reperfusion Catheter and the Penumbra System The Penumbra System with the ACE68 Reperfusion Catheter is indicated for use in the revascularization of patients with acute ischemic ...